Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer David Feller-Kopman, MD, Shan Liu, PhD, Benjamin P. Geisler, MD, Malcolm M. DeCamp, MD, Jan B. Pietzsch, PhD Journal of Thoracic Oncology Volume 12, Issue 8, Pages 1223-1232 (August 2017) DOI: 10.1016/j.jtho.2017.04.030 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
Figure 1 Representation of model structure (simplified). In the classifier strategy, classifier costs were considered only in the case of a nondiagnostic bronchoscopy result. VATS, video-assisted thoracoscopy; f/u: follow-up; TTNA, transthoracic needle aspiration. Journal of Thoracic Oncology 2017 12, 1223-1232DOI: (10.1016/j.jtho.2017.04.030) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
Figure 2 Projected absolute number of invasive procedures per patient for the two competing strategies at 1 month (left) and 2 years (right), and resulting relative reduction in procedures. Journal of Thoracic Oncology 2017 12, 1223-1232DOI: (10.1016/j.jtho.2017.04.030) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions